CDC's Opioid Stance Hurts Drug Cos. In Marketing Suits

Law360, New York (March 16, 2016, 9:37 PM EDT) -- The U.S. Centers for Disease Control and Prevention's latest push to decrease the prevalence of opioid painkillers primarily targets the prescribing habits of physicians, but opioid manufacturers will also feel its sting when plaintiffs brandish the high-profile agency's guidelines emphasizing the drugs' addictiveness to argue that their marketing was negligent or deceitful, attorneys say. 

The CDC on Tuesday issued a series of voluntary recommendations to discourage physicians from prescribing opioid painkillers, saying physicians should try to exhaust other treatment options before resorting to opioids and should generally prescribe them for no more than three days, even to alleviate severe pain such...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!